Levi & Korsinsky Investigates Intellia Therapeutics, Inc. for Potential Securities Law Violations
New York, NY – January 22, 2025
Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) for potential securities laws violations. The investigation focuses on certain statements made by Intellia in its press release issued on January 9, 2025, announcing its strategic priorities and key anticipated 2025 milestones.
Background
Intellia Therapeutics, Inc. is a leading genome editing company developing potential therapeutic and industrial applications using the CRISPR/Cas9 system. The Company’s mission is to leverage its proprietary CRISPR/Cas9 technology to develop therapeutics in various therapeutic areas, including hematology, neurology, and monogenic diseases.
Investigation Allegations
The investigation concerns whether Intellia and certain of its officers and/or directors made false and/or misleading statements and/or failed to disclose material information in the Company’s public filings, press releases, and other communications. Specifically, the investigation focuses on the Company’s statements regarding its business, operations, and prospects, including but not limited to:
- The Company’s ability to achieve its 2025 milestones, including the initiation of clinical trials for certain programs and the filing of regulatory submissions
- The Company’s financial projections and revenue expectations
- The Company’s assessment of the regulatory landscape and the potential impact on its business
Effects on Individual Investors
If it is determined that Intellia and its officers or directors have engaged in securities fraud or other unlawful business practices, the Company’s investors may be able to recover their losses through a securities class action lawsuit. Such a lawsuit could result in substantial compensation for investors, including monetary damages and potential recovery of attorneys’ fees and expenses.
Effects on the World
The investigation and potential securities fraud allegations against Intellia Therapeutics, Inc. could have far-reaching implications for the entire genome editing industry. If the allegations are proven true, it could potentially damage the reputation of the industry and raise concerns about the reliability of companies’ public statements regarding their financial projections and regulatory compliance. This could lead to increased regulatory scrutiny and potentially impact investor confidence in the sector as a whole.
Conclusion
Levi & Korsinsky is committed to safeguarding investors’ interests and ensuring that they are fully informed about any potential securities law violations and their legal rights. The investigation of Intellia Therapeutics, Inc. is ongoing, and the firm encourages investors with an investment in the Company to contact the firm to discuss their potential legal rights and options.
If you have invested in Intellia Therapeutics, Inc. and wish to discuss this investigation or have any questions regarding this notice or your legal rights, please contact Levi & Korsinsky, LLP by email at [email protected] or by telephone at (212) 363-7576, toll-free: (877) 363-5972. You may also visit the firm’s website at www.zlk.com for more information.
Forward-Looking Statements: This press release contains “forward-looking statements.” Forward-looking statements include any statements that may describe trends, conditions, or Intellia’s plans with respect to plans, objectives, assumptions, expectations, estimates, and intentions, and other statements that are not historical facts. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are based on current expectations and assumptions, which are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.
This press release does not constitute a solicitation or offer to sell or the solicitation of an offer to buy any securities or a recommendation of any security or investment strategy. Any offering or solicitation will be made only by means of a legal private placement memorandum and private placement subscription agreement. Nothing contained in this press release is or should be relied upon as a promise or representation as to the future performance or financial condition of Intellia.
Please note that this post is for informational purposes only and does not constitute legal advice. The information provided in this post is not intended to create, and receipt of this information does not constitute, an attorney-client relationship. You should not act upon any information in this post without seeking professional legal counsel.
Levi & Korsinsky LLPP. 1001 Brickell Bay Dr., Suite 2702, Miami, FL 33131. Tel: (305) 402-3330. Fax: (212) 363-7171. Email: [email protected].
ATTORNEY ADVERTISING. Prior results do not guarantee a similar outcome.
